Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | KDM6B | O15054 | 1/20 | 0.45 |
| ▸ | KDM6A | O15550 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 4/20 | 0.41 |
| ▸ | EEF2K | O00418 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759892 | 0.82 | HPGD (0.41) | MAPTKDM6BKDM6AL3MBTL1MEN1 | |
| SCHEMBL6762328 | 0.81 | MAOA (0.48) | MAPTKDM6BKDM6AL3MBTL1MEN1 | |
| SCHEMBL13522796 | 0.77 | KDM6B (0.73) | MAPTKDM6BKDM6APTGS2L3MBTL1 | |
| SCHEMBL13522992 | 0.74 | NPC1 (0.61) | MAPTKDM6BKDM6AMEN1KMT2A | |
| SCHEMBL6469733 | 0.73 | MAOA (0.49) | MAPTKDM6BKDM6APTGS2MEN1 | |
| SCHEMBL6469479 | 0.73 | MAOA (0.59) | MAPTKDM6BKDM6APTGS2MEN1 | |
| SCHEMBL10590299 | 0.70 | AGPAT2 (0.50) | MAPTSMN1; SMN2TP53 | |
| SCHEMBL13522990 | 0.69 | KDM4E (0.49) | MAPTKDM6BKDM6APTGS2L3MBTL1 | |
| SCHEMBL16348348 | 0.68 | EPHX2 (0.44) | MAPTKDM6BKDM6APIM1CDK5 | |
| SCHEMBL16203168 | 0.68 | KDM6B (0.67) | MAPTKDM6BKDM6AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723742-B2 | TREATMENT OF DISEASES WHICH CAUSE EXCESS OF IRON IN HUMAN OR ANIMAL BODY OR ARE CAUSED BY IT | NOVARTIS AG. (CH) | 2004-04-20 | — | — | US | disclosed |
| US-20030203954-A1 | Substituted 3, 5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | LATTMANN RENE (CH) | 2003-10-30 | — | — | US | disclosed |
| US-6596750-B2 | Compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals. | NOVARTIS AG (CH) | 2003-07-22 | — | — | US | disclosed |
| US-20030069273-A1 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | LATTMANN RENE (CH) | 2003-04-10 | — | — | US | disclosed |
| EP-0914118-B1 | SUBSTITUTED 3,5-DIPHENYL-1,2,4-TRIAZOLES AND THEIR USE AS PHARMACEUTICAL METAL CHELATORS | NOVARTIS AG (CH) | 2002-10-23 | — | — | EP | disclosed |
| US-6465504-B1 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | NOVARTIS AG (CH) | 2002-10-15 | — | — | US | disclosed |
| EP-0914118-A1 | SUBSTITUTED 3,5-DIPHENYL-1,2,4-TRIAZOLES AND THEIR USE AS PHARMACEUTICAL METAL CHELATORS | Novartis AG (CH) | 1999-05-12 | — | — | EP | disclosed |
| WO-1997049395-A1 | SUBSTITUTED 3,5-DIPHENYL-1,2,4-TRIAZOLES AND THEIR USE AS PHARMACEUTICAL METAL CHELATORS | NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. (AT) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069273-A1 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | TFRC, SLC40A1, FECH | MAPT 3676/4885KDM6B 2804/4885KDM6A 2279/4885 |
| US-20030203954-A1 | Substituted 3, 5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | TFRC, SLC40A1, FECH | MAPT 3676/4885KDM6B 2804/4885KDM6A 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.